Literature DB >> 24343712

Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society.

Toshihiro Sawai1, Masaomi Nangaku, Akira Ashida, Rika Fujimaru, Hiroshi Hataya, Yoshihiko Hidaka, Shinya Kaname, Hirokazu Okada, Waichi Sato, Takashi Yasuda, Yoko Yoshida, Yoshihiro Fujimura, Motoshi Hattori, Shoji Kagami.   

Abstract

Atypical hemolytic uremic syndrome (aHUS) is rare and comprises the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Recently, abnormalities in the mechanisms underlying complement regulation have been focused upon as causes of aHUS. The prognosis for patients who present with aHUS is very poor, with the first aHUS attack being associated with a mortality rate of ~25 %, and with ~50 % of cases resulting in end-stage renal disease requiring dialysis. If treatment is delayed, there is a high risk of this syndrome progressing to renal failure. Therefore, we have developed diagnostic criteria for aHUS to enable its early diagnosis and to facilitate the timely initiation of appropriate treatment. We hope these diagnostic criteria will be disseminated to as many clinicians as possible and that they will be used widely.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24343712     DOI: 10.1007/s10157-013-0911-8

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  14 in total

1.  [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia].

Authors:  C GASSER; E GAUTIER; A STECK; R E SIEBENMANN; R OECHSLIN
Journal:  Schweiz Med Wochenschr       Date:  1955-09-20

Review 2.  Atypical hemolytic-uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

3.  Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.

Authors:  Gema Ariceta; Nesrin Besbas; Sally Johnson; Diana Karpman; Daniel Landau; Christoph Licht; Chantal Loirat; Carmine Pecoraro; C Mark Taylor; Nicole Van de Kar; Johan Vandewalle; Lothar B Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-09-18       Impact factor: 3.714

4.  Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

Authors:  Marina Noris; Jessica Caprioli; Elena Bresin; Chiara Mossali; Gaia Pianetti; Sara Gamba; Erica Daina; Chiara Fenili; Federica Castelletti; Annalisa Sorosina; Rossella Piras; Roberta Donadelli; Ramona Maranta; Irene van der Meer; Edward M Conway; Peter F Zipfel; Timothy H Goodship; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

Review 5.  Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated?

Authors:  Carla M Nester; Christie P Thomas
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

6.  Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: a multicenter study.

Authors:  Osamu Uemura; Masataka Honda; Takeshi Matsuyama; Kenji Ishikura; Hiroshi Hataya; Nahoko Yata; Takuhito Nagai; Yohei Ikezumi; Naoya Fujita; Shuichi Ito; Kazumoto Iijima; Teruo Kitagawa
Journal:  Clin Exp Nephrol       Date:  2011-04-21       Impact factor: 2.801

Review 7.  Genetics and complement in atypical HUS.

Authors:  David Kavanagh; Tim Goodship
Journal:  Pediatr Nephrol       Date:  2010-06-06       Impact factor: 3.714

8.  Vero response to a cytotoxin of Escherichia coli.

Authors:  J Konowalchuk; J I Speirs; S Stavric
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

9.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Authors:  C M Legendre; C Licht; P Muus; L A Greenbaum; S Babu; C Bedrosian; C Bingham; D J Cohen; Y Delmas; K Douglas; F Eitner; T Feldkamp; D Fouque; R R Furman; O Gaber; M Herthelius; M Hourmant; D Karpman; Y Lebranchu; C Mariat; J Menne; B Moulin; J Nürnberger; M Ogawa; G Remuzzi; T Richard; R Sberro-Soussan; B Severino; N S Sheerin; A Trivelli; L B Zimmerhackl; T Goodship; C Loirat
Journal:  N Engl J Med       Date:  2013-06-06       Impact factor: 91.245

Review 10.  Atypical hemolytic uremic syndrome.

Authors:  Chantal Loirat; Véronique Frémeaux-Bacchi
Journal:  Orphanet J Rare Dis       Date:  2011-09-08       Impact factor: 4.123

View more
  11 in total

1.  Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma.

Authors:  Adarsh Das; Andrew Dean; Tim Clay
Journal:  BMJ Case Rep       Date:  2019-04-08

Review 2.  Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology.

Authors:  Masashi Mizuno; Yasuhiro Suzuki; Yasuhiko Ito
Journal:  Clin Exp Nephrol       Date:  2017-03-24       Impact factor: 2.801

3.  Clinical guides for atypical hemolytic uremic syndrome in Japan.

Authors:  Hideki Kato; Masaomi Nangaku; Hiroshi Hataya; Toshihiro Sawai; Akira Ashida; Rika Fujimaru; Yoshihiko Hidaka; Shinya Kaname; Shoichi Maruyama; Takashi Yasuda; Yoko Yoshida; Shuichi Ito; Motoshi Hattori; Yoshitaka Miyakawa; Yoshihiro Fujimura; Hirokazu Okada; Shoji Kagami
Journal:  Clin Exp Nephrol       Date:  2016-08       Impact factor: 2.801

4.  Controversies of the classification of TMA and the terminology of aHUS.

Authors:  Hideki Kato; Masaomi Nangaku; Hirokazu Okada; Shoji Kagami
Journal:  Clin Exp Nephrol       Date:  2017-12-27       Impact factor: 2.801

5.  Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.

Authors:  Naoko Ito; Hiroshi Hataya; Ken Saida; Yoshiro Amano; Yoshihiko Hidaka; Yaeko Motoyoshi; Toshiyuki Ohta; Yasuhiro Yoshida; Chikako Terano; Tadashi Iwasa; Wataru Kubota; Hidetoshi Takada; Toshiro Hara; Yoshihiro Fujimura; Shuichi Ito
Journal:  Clin Exp Nephrol       Date:  2015-07-09       Impact factor: 2.801

6.  Clinical characteristics, triggering etiologies, and response of plasmapheresis in thrombotic microangiopathy in Taiwan.

Authors:  Ching-Hu Chung; I-Jung Tsai; Min-Hua Tseng; Hsin-Hsu Chou; You-Lin Tain; Jeng-Daw Tsai; Yuan-Yow Chiou; Yee-Hsuan Chiou; Ching-Yuang Lin
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

Review 7.  Atypical hemolytic-uremic syndrome: a case report and literature review.

Authors:  Arsalan Rafiq; Hassan Tariq; Naeem Abbas; Roopalekha Shenoy
Journal:  Am J Case Rep       Date:  2015-02-24

8.  A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan.

Authors:  Yoko Yoshida; Toshiyuki Miyata; Masanori Matsumoto; Hiroko Shirotani-Ikejima; Yumiko Uchida; Yoshifumi Ohyama; Tetsuro Kokubo; Yoshihiro Fujimura
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

9.  Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome.

Authors:  Madoka Fujisawa; Hideki Kato; Yoko Yoshida; Tomoko Usui; Munenori Takata; Mika Fujimoto; Hideo Wada; Yumiko Uchida; Koichi Kokame; Masanori Matsumoto; Yoshihiro Fujimura; Toshiyuki Miyata; Masaomi Nangaku
Journal:  Clin Exp Nephrol       Date:  2018-03-06       Impact factor: 2.801

Review 10.  Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome.

Authors:  Hajeong Lee; Eunjeong Kang; Hee Gyung Kang; Young Hoon Kim; Jin Seok Kim; Hee-Jin Kim; Kyung Chul Moon; Tae Hyun Ban; Se Won Oh; Sang Kyung Jo; Heeyeon Cho; Bum Soon Choi; Junshik Hong; Hae Il Cheong; Doyeun Oh
Journal:  Korean J Intern Med       Date:  2020-01-02       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.